Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.75
Bid: 14.50
Ask: 15.00
Change: -0.25 (-1.67%)
Spread: 0.50 (3.448%)
Open: 15.25
High: 15.25
Low: 14.75
Prev. Close: 15.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

27 Nov 2009 07:00

RNS Number : 1665D
Angle PLC
27 November 2009
 



For immediate release

27 November 2009

ANGLE plc ("the Company")

Contract Win

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and innovation, is delighted to announce a new contract win for its Management Services business worth £2.3 million over three years.

The contract, which was the subject of a competitive tendering process, is to deliver Innovation Advice and Guidance in Lincolnshire, a product in the UK Government's Solutions for Business portfolio, on behalf of Lincolnshire County Council. The contract follows ANGLE's successful delivery oa previous programme, Innovation Lincolnshire, since May 2007. 

 

The programme brings the techniques and benefits of innovation to small businesses, identifying openings for innovation based business improvement. These include stimulating growth through the introduction of new products and services and delivering operational improvement through innovative business process change.  ANGLE's specialist consultants provide complete SME innovation support service, from innovation opportunity identification, training, business analysis and support to project implementation.

Innovation is considered by Lincolnshire's public sector partners to be crucial to the county's development and prosperityDeveloped as part of the Lincolnshire Economic Strategy, the Programme is part of the county's  contribution to the East Midlands Regional Innovation Strategy.

Commenting on the award of this new contract, Programme Director Dr Shane Booth said: 

"We are delighted to have been given the opportunity to continue working with delivery partners and businesses across Lincolnshire. Our success in securing this contract reflects the methodologies, delivery processes, expertise and management we have developed to drive innovation. In the earlier programme, we deployed these to assist projects as diverse as the development of new musical instruments, designing special packaging to redeploy a bulk product for retail sale and the creation of a new, mobile biomass heating system."

ANGLE Founder and Chief Executive, Andrew Newland, added:

"This contract confirms the attraction of our capabilities and approach to public sector organisations seeking to deploy technology and innovation as tools for business growth and consequent regional economic development. Our strategy of focusing on long term contracts in cases where we can add substantial value continues to be highly successful for ANGLE. We look forward to the potential of rolling out these capabilities throughout the UK and beyond."

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Stewart Wallace

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

Notes to Editors

ANGLE plc 

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

ANGLE also owns a portfolio of companies with high growth potential in the medical and technology sectors in both the UK and the US. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

ANGLE's venture management and technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, clean tech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUNRNRKORAUAA
Date   Source Headline
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.